Comparative Pharmacology
Head-to-head clinical analysis: DIATRIZOATE MEGLUMINE versus OMNIPAQUE 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIATRIZOATE MEGLUMINE versus OMNIPAQUE 300.
DIATRIZOATE MEGLUMINE vs OMNIPAQUE 300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diatrizoate meglumine is an ionic, high-osmolar iodinated contrast agent that absorbs X-rays due to its iodine content, thereby enhancing radiographic imaging. It does not exert pharmacological effects via receptor interaction but functions by attenuating X-ray beams, providing contrast between vascular structures and surrounding tissues.
Iodinated contrast agent that attenuates X-rays, providing vascular and tissue opacification by increasing the density of blood vessels and organs.
Intravenous: 1-2 mL/kg (305-610 mg I/kg) of 60% or 76% solution for urography; 40-60 mL of 50% solution for retrograde cystourethrography. Oral: 200-600 mL of 4.8% suspension for GI contrast.
Intravenous: 1-2 mL/kg (300 mg I/mL) for contrast-enhanced CT; intra-arterial: 5-80 mL per injection depending on procedure; maximum total dose 4 mL/kg.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours in patients with normal renal function (CLcr >90 mL/min). Half-life is significantly prolonged in renal impairment (up to 20-40 hours in anuria), necessitating dose adjustment and caution.
The terminal elimination half-life of iohexol in patients with normal renal function (creatinine clearance > 90 mL/min) is approximately 1.5 to 2 hours. In patients with renal impairment, the half-life is significantly prolonged (up to 30 hours or more in severe renal failure), necessitating dose adjustment and careful monitoring.
Primarily renal excretion via glomerular filtration; >95% of the administered dose is excreted unchanged in urine within 24 hours. Less than 5% is excreted in feces via biliary elimination.
Omnipaque 300 (iohexol) is primarily eliminated unchanged by the kidneys via glomerular filtration. Renal excretion accounts for >95% of the administered dose within 24 hours in patients with normal renal function. Fecal excretion is negligible (<1%). Billiary excretion is minimal, with less than 0.1% recovered in bile or feces.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent